BRL 501
Alternative Names: BRL-501Latest Information Update: 04 Jan 2024
At a glance
- Originator BRL Medicine
- Class Antineoplastics; CAR-T cell therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Prostate cancer
Most Recent Events
- 19 Dec 2023 Preclinical trials in Prostate cancer in China (Parenteral) (Prior to December 2023)(BRL Medicine Pipeline, December 2023)